奈玛特韦/利托那韦相关不良反应文献分析
Literature analysis of adverse drug reactions related to nirmatrelvir/ritonavir
张伊楠 1武明芬 1李草 1赵志刚2
作者信息
- 1. 首都医科大学附属北京天坛医院药学部,北京 100070
- 2. 首都医科大学附属北京天坛医院药学部,北京 100070;首都医科大学药学院临床药学系,北京 100069
- 折叠
摘要
目的:分析奈玛特韦/利托那韦相关药物不良反应(adverse drug reaction,ADR)的特点,为临床合理用药提供参考.方法:检索建库起至 2023 年 1 月中国知网、万方数据库、维普网、PubMed、Web of Sci-ence数据库,收集奈玛特韦/利托那韦相关ADR个案报道,提取文献资料进行统计分析.结果:共纳入文献17 篇,共计18 例患者.其中男性6 例,女性12 例,患者年龄为14～80 岁,其中71～80 岁年龄段比例最高.2 例怀疑为奈玛特韦/利托那韦导致的ADR,累及神经系统和心脏器官;16 例为与其他药物相互作用导致的ADR,相互作用药物为免疫抑制剂11 例,钙通道阻滞剂2 例,抗肿瘤药物、抗精神病药、血脂调节剂各1 例.经停药或对症支持治疗均治愈.结论:奈玛特韦/利托那韦的安全性仍需要进一步监测与研究,临床使用中需重点关注可能的药物相互作用,减少ADR的发生.
Abstract
Objective:To analyze the characteristics of adverse drug reactions(ADRs)related to nirmatrelvir/ritonavir in order to provide references for rational clinical drug use.Methods:The databases of CNKI,Wanfang,VIP,PubMed and Web of Science were searched to collect case reports of ADR related to nirmatrelvir/ritonavir from the establishment of the database up to January 2023.The literature was extracted for statistical analysis.Results:A total of 17 articles were included,involving 18 patients,6 males and 12 females.The age of the patients ranged 14 to 80 years,with the highest proportion in the age group of 71～80 years.ADRs occurring in neural and cardiac systems from 2 cases were suspected caused by nirmatrelvir/ritonavir.ADRs in sixteen cases were induced by the drug-drug interaction of nirmatrelvir/ritonavir.Drugs that are involved in the drug interactions were immunosuppressants in 11 cases,calcium channel blockers in 2 cases,antineoplastic agents,antipsychotics,and lipid modifying agent in 1 case each.All patients were cured after drug withdrawal or receiving symptomatic and supportive treatment.Conclusion:The safety of nirmatrelvir/ritonavir still requires further monitoring and study.Attention should be paid to possible drug interactions in clinical use to reduce the occurrence of adverse reactions.
关键词
奈玛特韦/利托那韦/新型冠状病毒/不良反应/药物相互作用Key words
nirmatrelvir/ritonavir/COVID-19/adverse drug reaction/drug-drug interaction引用本文复制引用
基金项目
中国药品监督管理研究会立项课题资助项目(2022-yy-010)
出版年
2024
NETL
NSTL
万方数据